Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Better Buy: Gilead or Amgen?

In the following video, Fool contributor Maxx Chatsko explains whether he thinks Gilead Sciences (NASDAQ: GILD  ) or Amgen (NASDAQ: AMGN  ) is the better buy. Both companies are trading at nearly identical market caps and have risen dramatically since the beginning of 2012 in anticipation of new blockbuster products. Both have robust pipelines stuffed full of potential at all levels of development. This is going to be a tough decision. If these companies are on your watchlist or if you're simply looking to add to a position, then you may want to use the current market volatility to your advantage.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

Read/Post Comments (2) | Recommend This Article (6)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On June 25, 2013, at 3:14 PM, DrGoldin wrote:

    One point that I think you should have added: you're right when you say that Amgen and Gilead have similar valuations ($72B for Amgen and and $75.9B for Gilead), but their trailing p/e's are in totally different ballparks: 16.26 for Amgen vs. 32.46 for Gilead. This only supports your theme that a whole lot of optimism is already built into Gilead's share price. (If you look at future p/e projections, the gap starts to narrow quickly.)

    I'd still go with Gilead though. What's that saying? Better to get a great company at a good price than a good company at a great price.

  • Report this Comment On June 26, 2013, at 8:45 AM, TMFBlacknGold wrote:


    I thought I pointed out P/E in the video (it was in my bullet points if I did skip over it during filming). But I certainly admit that it is a close call. Also, you remind me that I need to get back into CAPS!

    Take care and Fool on!


Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2508723, ~/Articles/ArticleHandler.aspx, 9/26/2016 10:17:36 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,115.07 -146.38 -0.80%
S&P 500 2,152.45 -12.24 -0.57%
NASD 5,263.26 -42.49 -0.80%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/26/2016 10:01 AM
AMGN $173.33 Down -1.47 -0.84%
Amgen CAPS Rating: ****
GILD $80.46 Down -0.91 -1.12%
Gilead Sciences CAPS Rating: *****